const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_WIDE"; // 13.3" x 7.5"

// ─── Color Palette ───────────────────────────────────────────────────────────
const C = {
  bg:       "0A1628",   // deep navy
  panel:    "0D1F3C",   // card bg
  panelAlt: "0E2445",
  accent1:  "E8383D",   // red
  accent2:  "F4A61A",   // amber
  accent3:  "27AE60",   // green
  accent4:  "2E86DE",   // blue
  accent5:  "9B59B6",   // purple
  accent6:  "E67E22",   // orange
  accent7:  "1ABC9C",   // teal
  accent8:  "E74C3C",   // crimson
  accent9:  "3498DB",   // sky
  accent10: "8E44AD",   // violet
  white:    "FFFFFF",
  lightGray:"C8D6E5",
  yellow:   "F9CA24",
  hdr:      "152744",
};

// ─── Drug Data ────────────────────────────────────────────────────────────────
const drugs = [
  {
    name: "LABETALOL",
    color: C.accent1,
    category: "α/β-Blocker | Antihypertensive",
    mechanism: "Non-selective β-blocker + selective α1-blocker → ↓ HR, ↓ SVR, ↓ BP",
    indications: "Hypertensive emergencies, pre-eclampsia/eclampsia, aortic dissection, phaeochromocytoma crisis",
    contraindications: "Asthma, COPD, 2nd/3rd° AV block, cardiogenic shock, bradycardia <50/min, decompensated HF",
    dose: "IV: 20 mg bolus over 2 min; repeat 40–80 mg q10 min\nInfusion: 1–2 mg/min",
    maxDose: "Bolus max: 300 mg total | Infusion: 300 mg/session",
    dilution: "200 mg in 200 mL NS/D5W (1 mg/mL) or undiluted 5 mg/mL for bolus",
    shelfLife: "Undiluted: 2 years | Diluted: 24 h (room temp) / 48 h (refrigerated)",
    halfLife: "5–8 hours",
  },
  {
    name: "METOCLOPRAMIDE",
    color: C.accent2,
    category: "Prokinetic | Antiemetic | D2-Antagonist",
    mechanism: "Central & peripheral D2-receptor antagonist + 5-HT3 antagonist → ↑ gastric motility, ↑ lower oesophageal tone, antiemetic",
    indications: "Nausea/vomiting, gastroparesis, GORD, post-op ileus, migraine headache (adjunct), pre-procedural gastric emptying",
    contraindications: "GI obstruction/perforation, phaeochromocytoma, Parkinson's disease, seizure disorders, tardive dyskinesia hx",
    dose: "IV/IM: 10 mg over 1–2 min; Oral: 10 mg TDS ac\nCRI: 25–75 mg/24 h",
    maxDose: "30 mg/day (adult) | 0.5 mg/kg/day (paediatric)",
    dilution: "10 mg in 50 mL NS slow IV push or diluted in 50 mL over 15 min",
    shelfLife: "Undiluted: 3 years | Diluted: 48 h protected from light",
    halfLife: "5–6 hours",
  },
  {
    name: "TRAMADOL",
    color: C.accent3,
    category: "Opioid Agonist | SNRI | Analgesic",
    mechanism: "Weak μ-opioid receptor agonist + inhibits reuptake of serotonin & noradrenaline → central analgesia",
    indications: "Moderate–severe pain (acute & chronic), post-op pain, neuropathic pain, labour analgesia (limited)",
    contraindications: "MAOIs (within 14 days), seizure disorder, raised ICP, respiratory depression, serotonin syndrome risk, <12 yrs",
    dose: "IV: 50–100 mg over 10–20 min q4–6 h\nOral: 50–100 mg q6 h\nMax: 400 mg/day",
    maxDose: "400 mg/day (oral); 600 mg/day (IV under supervision)",
    dilution: "100 mg in 100 mL NS over 30 min (to reduce nausea)",
    shelfLife: "Undiluted: 3 years | Diluted: 24 h",
    halfLife: "6–7 h (active metabolite O-desmethyl-tramadol: ~9 h)",
  },
  {
    name: "AVIL (Pheniramine)",
    color: C.accent4,
    category: "H1-Antihistamine | Antiallergic",
    mechanism: "Competitive H1-receptor antagonist → blocks histamine-mediated vasodilation, bronchoconstriction, pruritus, oedema",
    indications: "Allergic reactions, anaphylaxis (adjunct), urticaria, angioedema, pruritus, transfusion reactions, insect bites",
    contraindications: "Acute asthma attack (use with caution), neonates, nursing mothers, MAOIs, glaucoma, BPH",
    dose: "IM/IV: 22.75 mg (1 mL) to 45.5 mg (2 mL) slow IV\nOral: 25–50 mg BD–TDS",
    maxDose: "100 mg/24 h (IV) | 200 mg/24 h (oral)",
    dilution: "Dilute in 10 mL NS and give over 2–3 min IV; IM can be given undiluted",
    shelfLife: "3 years | Diluted: 8 h",
    halfLife: "16–19 hours",
  },
  {
    name: "TRANEXAMIC ACID",
    color: C.accent5,
    category: "Antifibrinolytic | Haemostatic",
    mechanism: "Inhibits conversion of plasminogen → plasmin by blocking lysine binding sites → prevents fibrin clot dissolution",
    indications: "Trauma haemorrhage (within 3 h of injury), PPH, surgical bleeding, epistaxis, haemoptysis, menorrhagia (heavy periods)",
    contraindications: "Active thromboembolic disease (DVT/PE), history of seizures (high dose), subarachnoid haemorrhage (controversial), renal failure (reduce dose)",
    dose: "Trauma/PPH: 1 g IV over 10 min STAT; 2nd dose: 1 g over 8 h\nSurgery: 1–1.5 g IV pre-op",
    maxDose: "2 g per episode (trauma); 3–4 g/day (surgical)",
    dilution: "1 g (10 mL) in 100 mL NS or D5W; give over 10–20 min (NOT rapid bolus → convulsions)",
    shelfLife: "4–5 years | Diluted: 8 h at room temp",
    halfLife: "2–3 hours",
  },
  {
    name: "TAPENTADOL",
    color: C.accent6,
    category: "Opioid Agonist | NRI | Strong Analgesic",
    mechanism: "Dual: μ-opioid receptor agonist + noradrenaline reuptake inhibitor → multimodal central analgesia",
    indications: "Moderate–severe acute pain, chronic musculoskeletal pain, neuropathic pain, post-op pain, diabetic neuropathy",
    contraindications: "MAOIs (within 14 days), severe asthma/COPD, respiratory depression, paralytic ileus, <18 yrs (IR), epilepsy",
    dose: "Oral IR: 50–100 mg q4–6 h; 2nd dose 1 h after 1st if needed\nOral ER: 50–250 mg BD",
    maxDose: "700 mg on day 1; 600 mg/day thereafter (IR) | 500 mg/day (ER)",
    dilution: "Oral form only (no IV preparation); take with or without food",
    shelfLife: "3 years",
    halfLife: "4–5 hours",
  },
  {
    name: "PHENYTOIN",
    color: C.accent7,
    category: "Antiepileptic | Anticonvulsant | Class IB Antiarrhythmic",
    mechanism: "Blocks voltage-gated Na⁺ channels (use-dependent) → ↓ neuronal membrane excitability → suppresses epileptiform firing",
    indications: "Status epilepticus (2nd line), generalised tonic-clonic & partial seizures, post-neurosurgical seizure prophylaxis, digoxin-induced arrhythmia",
    contraindications: "2nd/3rd° AV block, sinus bradycardia, Adams-Stokes syndrome, concurrent delavirdine, hypersensitivity",
    dose: "Loading: 15–20 mg/kg IV at ≤50 mg/min\nMaintenance: 4–6 mg/kg/day divided BD–TDS",
    maxDose: "Loading: 30 mg/kg | Rate: NEVER exceed 50 mg/min (cardiac arrhythmias)",
    dilution: "Dilute in NS ONLY (NOT D5W — precipitates!); final conc ≤6.7 mg/mL; use 0.22 µm in-line filter",
    shelfLife: "2–5 years | Diluted: Use within 1 h",
    halfLife: "7–42 h (dose-dependent, saturation kinetics)",
  },
  {
    name: "LORAZEPAM",
    color: C.accent8,
    category: "Benzodiazepine | Anticonvulsant | Anxiolytic",
    mechanism: "Positive allosteric modulator of GABA-A receptor → ↑ Cl⁻ influx → CNS depression, anticonvulsant, anxiolytic",
    indications: "Status epilepticus (1st line IV), acute anxiety, procedural sedation, alcohol withdrawal seizures, pre-anaesthetic",
    contraindications: "Acute angle-closure glaucoma, myasthenia gravis, severe respiratory depression, sleep apnoea, polysubstance overdose, 1st trimester pregnancy",
    dose: "Seizure: 0.1 mg/kg IV (usual 4 mg); may repeat x1 after 5 min\nAnxiety: 0.5–2 mg IV/IM q6–8 h",
    maxDose: "8 mg total per episode (seizure); 10 mg/day (anxiety)",
    dilution: "Dilute 1:1 with NS, D5W or sterile water for IV; give ≤2 mg/min",
    shelfLife: "2–3 years | Diluted: 24 h refrigerated; expires rapidly at room temp",
    halfLife: "10–20 hours (no active metabolite)",
  },
  {
    name: "ONDANSETRON",
    color: C.accent9,
    category: "5-HT3 Antagonist | Antiemetic",
    mechanism: "Selective 5-HT3 antagonist (peripheral vagal afferents + central CTZ) → blocks serotonin-mediated emetic reflex",
    indications: "Post-op N&V, chemotherapy/radiotherapy-induced N&V, intractable N&V, pre-procedural, gastroenteritis vomiting",
    contraindications: "Congenital long QT syndrome, concurrent apomorphine (fatal hypotension), caution with other QT-prolonging drugs",
    dose: "IV: 4–8 mg over 15 min (PON&V); 8 mg over 15 min (chemo)\nOral: 8 mg BD–TDS",
    maxDose: "32 mg/day (single IV dose ≤16 mg); IV single dose now capped at 32 mg (FDA safety)",
    dilution: "4–8 mg in 50 mL NS or D5W over 15 min; undiluted 2 mg/mL for slow push",
    shelfLife: "3–5 years | Diluted: 48 h (2–8°C) or 24 h (room temp)",
    halfLife: "3–6 hours",
  },
  {
    name: "NORADRENALINE",
    color: C.accent10,
    category: "Vasopressor | α1/α2/β1-Agonist",
    mechanism: "Potent α1 + α2 agonist (↑↑ SVR, vasoconstriction) + mild β1 (slight ↑ HR, ↑ contractility) → ↑↑ MAP, ↑ CO",
    indications: "Septic shock (1st-line vasopressor), neurogenic shock, refractory hypotension, distributive shock",
    contraindications: "Hypovolaemia (correct first), mesenteric/peripheral vascular thrombosis, cyclopropane/halothane anaesthesia",
    dose: "Start: 0.01–0.05 mcg/kg/min; titrate to MAP ≥65 mmHg\nUsual range: 0.1–2 mcg/kg/min",
    maxDose: "3–5 mcg/kg/min (no absolute max; titrate to effect; high dose → excessive vasoconstriction)",
    dilution: "4–8 mg in 250 mL D5W/NS (16–32 mcg/mL); ALWAYS via central line ideally",
    shelfLife: "18 months | Diluted: 24 h protected from light",
    halfLife: "~2–3 minutes",
  },
  {
    name: "ADRENALINE (Epinephrine)",
    color: C.accent1,
    category: "α/β-Agonist | Vasopressor | Bronchodilator",
    mechanism: "α1: vasoconstriction (↑ MAP); β1: ↑ HR, ↑ contractility; β2: bronchodilation, ↓ mast cell mediators",
    indications: "Anaphylaxis (1st-line IM), cardiac arrest (VF/pVT/PEA), cardiogenic shock, severe bronchospasm, croup (nebulised)",
    contraindications: "No absolute contraindications in life-threatening emergencies; relative: arrhythmias, coronary artery disease, thyrotoxicosis",
    dose: "Anaphylaxis: 0.5 mg IM (0.5 mL 1:1,000) thigh\nCardiac arrest: 1 mg IV q3–5 min (1:10,000)\nInfusion: 0.01–1 mcg/kg/min",
    maxDose: "No fixed max in cardiac arrest; Anaphylaxis: repeat 0.5 mg IM q5 min PRN",
    dilution: "Infusion: 1 mg (1 mL 1:1,000) in 100 mL NS (10 mcg/mL); Cardiac arrest: 10 mL of 1:10,000 (0.1 mg/mL)",
    shelfLife: "18–24 months | Diluted: 24 h (protect from light); ampoules expire with oxidation",
    halfLife: "~2–3 minutes",
  },
  {
    name: "DOBUTAMINE",
    color: C.accent3,
    category: "β1/β2-Agonist | Inotrope | Cardiogenic Support",
    mechanism: "Selective β1 + mild β2 agonist → ↑ myocardial contractility, ↑ CO, ↓ SVR; minimal chronotropic effect",
    indications: "Cardiogenic shock, acute decompensated HF with ↓ CO, post-cardiac surgery low output, stress echocardiography",
    contraindications: "Hypertrophic obstructive cardiomyopathy (HOCM), uncorrected hypovolaemia, AF/flutter (can worsen), severe aortic stenosis",
    dose: "Start 2.5 mcg/kg/min; usual 2.5–20 mcg/kg/min\nTitrate to CO/clinical response",
    maxDose: "40 mcg/kg/min (rarely needed beyond 20)",
    dilution: "250 mg in 250 mL D5W/NS (1 mg/mL); do NOT mix with sodium bicarbonate (inactivation)",
    shelfLife: "2 years | Diluted: 24 h at room temp (can turn pinkish — stable if mild discolouration)",
    halfLife: "~2 minutes",
  },
  {
    name: "DOPAMINE",
    color: C.accent2,
    category: "Catecholamine | Dose-Dependent Vasopressor/Inotrope",
    mechanism: "Low dose (≤5): D1/D2 → renal/mesenteric vasodilation; Mid (5–10): β1 → ↑ CO; High (>10): α1 → ↑ SVR",
    indications: "Cardiogenic shock, septic shock (2nd-line), haemodynamic support post-cardiac surgery, bradycardia (adjunct)",
    contraindications: "Phaeochromocytoma, uncorrected tachyarrhythmias/VF, hypovolaemia (correct first), MAOIs within 14 days",
    dose: "Low (renal): 1–5 mcg/kg/min | Inotropic: 5–10 mcg/kg/min | Vasopressor: 10–20 mcg/kg/min",
    maxDose: "50 mcg/kg/min (extreme; titrate to response)",
    dilution: "400–800 mg in 250 mL D5W/NS; use infusion pump; extravasation → phentolamine",
    shelfLife: "2–3 years | Diluted: 24 h at room temp",
    halfLife: "~2 minutes",
  },
  {
    name: "ATROPINE",
    color: C.accent4,
    category: "Anticholinergic | Parasympatholytic | Antidote",
    mechanism: "Competitive muscarinic receptor antagonist → ↑ HR (blocks vagal tone), ↓ secretions, bronchodilation, mydriasis, ↓ GI motility",
    indications: "Symptomatic bradycardia (sinus, AV block 2°/3°), organophosphate/nerve agent poisoning, pre-op antisecretory, CPR (historical – now limited)",
    contraindications: "Angle-closure glaucoma, myasthenia gravis, tachycardia, urinary retention, GI obstruction, pyloric stenosis",
    dose: "Bradycardia: 0.5–1 mg IV q3–5 min\nOrganophosphate: 2–4 mg IV q5–10 min (titrate to dry secretions)\nPaeds: 0.02 mg/kg IV",
    maxDose: "Bradycardia: 3 mg total | OP poisoning: no upper limit (titrate secretions)",
    dilution: "Undiluted (0.6 mg/mL or 1 mg/mL ampoule); may dilute in 10 mL NS; give rapid IV push",
    shelfLife: "3–5 years | Diluted: 24 h",
    halfLife: "2–3 hours",
  },
  {
    name: "NITROGLYCERIN (GTN)",
    color: C.accent5,
    category: "Organic Nitrate | Vasodilator | Antianginal",
    mechanism: "Releases NO → activates guanylyl cyclase → ↑ cGMP → smooth muscle relaxation → venodilation (low dose) + arteriodilation (high dose) → ↓ preload, ↓ afterload",
    indications: "Acute angina/ACS, STEMI (adjunct), hypertensive emergency with ACS, decompensated HF (↑ filling pressures), oesophageal spasm",
    contraindications: "Systolic BP <90 mmHg, RV infarct, PDE-5 inhibitors (sildenafil/tadalafil within 24–48 h), severe aortic stenosis, raised ICP",
    dose: "SL: 0.4 mg q5 min × 3 doses\nIV infusion: 5–200 mcg/min (start 5–10 mcg/min, titrate)",
    maxDose: "SL: 3 doses; IV: 400 mcg/min (haemodynamic guidance)",
    dilution: "50 mg in 250 mL D5W (200 mcg/mL); use glass bottles + non-PVC tubing (adsorbs to PVC)",
    shelfLife: "2–3 years | Diluted: 24 h (glass, non-PVC); SL tabs: 6–12 months after opening",
    halfLife: "1–3 minutes (IV); ~20 min (patch)",
  },
  {
    name: "IV FLUIDS",
    color: C.accent7,
    category: "Volume Resuscitation | Electrolyte Balance",
    mechanism: "NS (0.9%): isotonic → expands ECF (limited to 25% intravascular); Hartmann's/LR: balanced crystalloid; Colloids: oncotic expansion; Albumin: oncotic + anti-inflammatory",
    indications: "Hypovolaemia, shock resuscitation, surgical maintenance, electrolyte replacement, drug dilution, DKA, burns, sepsis",
    contraindications: "Pulmonary oedema (excess), NS in hyperchloraemic acidosis, D5W in cerebral oedema/hyponatraemia, hyperaldosteronism",
    dose: "Resuscitation: 500 mL crystalloid bolus IV over 15 min; reassess\nMaintenance: 25–30 mL/kg/day adults\nDKA: 1 L NS over 1st h",
    maxDose: "Goal-directed (avoid fluid overload); limit NS to prevent hyperchloraemic acidosis",
    dilution: "Ready to use; warm to 37°C for large volumes; compatibility check before adding drugs",
    shelfLife: "2–5 years (sealed) | Once opened: use within session",
    halfLife: "NS: t½ intravascular ~1 h; Albumin: ~16–24 h",
  },
];

// ─── Slide dimensions ─────────────────────────────────────────────────────────
const SW = 13.3, SH = 7.5;

// ─── SLIDE 1: COVER ──────────────────────────────────────────────────────────
{
  const slide = pres.addSlide();
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: SH, fill: { color: C.bg } });

  // Top accent bar
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: 0.08, fill: { color: C.accent1 } });
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0.08, w: SW, h: 0.04, fill: { color: C.accent2 } });

  // Title
  slide.addText("EMERGENCY DRUG", {
    x: 0.5, y: 1.2, w: 12.3, h: 1.2,
    fontSize: 64, bold: true, color: C.white,
    align: "center", fontFace: "Arial",
    charSpacing: 12,
  });
  slide.addText("QUICK REFERENCE CHART", {
    x: 0.5, y: 2.5, w: 12.3, h: 0.9,
    fontSize: 36, bold: true, color: C.accent2,
    align: "center", fontFace: "Arial",
    charSpacing: 6,
  });

  // Subtitle line
  slide.addShape(pres.shapes.RECTANGLE, { x: 3.5, y: 3.6, w: 6.3, h: 0.04, fill: { color: C.accent4 } });

  slide.addText("Mechanism • Indications • Contraindications • Dose • Max Dose • Dilution • Shelf Life • Half-Life", {
    x: 0.5, y: 3.75, w: 12.3, h: 0.6,
    fontSize: 16, color: C.lightGray,
    align: "center", fontFace: "Arial", italic: true,
  });

  // Drug list
  const drugNames = drugs.map(d => d.name).join("  •  ");
  slide.addText(drugNames, {
    x: 0.5, y: 4.55, w: 12.3, h: 0.5,
    fontSize: 11, color: C.accent7,
    align: "center", fontFace: "Arial",
  });

  // Drug count badges
  const badges = ["16 Drugs", "Complete Reference", "ICU / Emergency Use"];
  badges.forEach((b, i) => {
    const bx = 2.2 + i * 3.1;
    slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x: bx, y: 5.3, w: 2.6, h: 0.5,
      fill: { color: C.hdr }, rectRadius: 0.1,
      line: { color: C.accent4, width: 1 },
    });
    slide.addText(b, {
      x: bx, y: 5.3, w: 2.6, h: 0.5,
      fontSize: 12, color: C.accent4, bold: true,
      align: "center", valign: "middle",
    });
  });

  slide.addText("For educational purposes | Always verify local protocols and current guidelines", {
    x: 0.5, y: 7.0, w: 12.3, h: 0.35,
    fontSize: 10, color: "5A7A9C", align: "center", italic: true,
  });
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: SH - 0.08, w: SW, h: 0.08, fill: { color: C.accent3 } });
}

// ─── SLIDES 2–17: One drug per slide ─────────────────────────────────────────
drugs.forEach((drug, idx) => {
  const slide = pres.addSlide();
  const col = drug.color;

  // Background
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: SH, fill: { color: C.bg } });

  // Top colour bar
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: 0.55, fill: { color: col } });

  // Drug number badge
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 0.18, y: 0.08, w: 0.4, h: 0.38,
    fill: { color: C.bg }, rectRadius: 0.05,
  });
  slide.addText(`${idx + 1}`, {
    x: 0.18, y: 0.08, w: 0.4, h: 0.38,
    fontSize: 12, bold: true, color: col,
    align: "center", valign: "middle",
  });

  // Drug name
  slide.addText(drug.name, {
    x: 0.7, y: 0.04, w: 9.5, h: 0.5,
    fontSize: 26, bold: true, color: C.white,
    fontFace: "Arial", valign: "middle", margin: 0,
  });

  // Category badge
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 10.25, y: 0.08, w: 2.85, h: 0.38,
    fill: { color: C.bg }, rectRadius: 0.05,
  });
  slide.addText(drug.category, {
    x: 10.25, y: 0.08, w: 2.85, h: 0.38,
    fontSize: 9, color: col, bold: true,
    align: "center", valign: "middle", wrap: true,
  });

  // ── Grid layout: 4 columns × 2 rows of info cards
  const cards = [
    { label: "⚙️ MECHANISM",           value: drug.mechanism,          col: C.accent4 },
    { label: "✅ INDICATIONS",          value: drug.indications,        col: C.accent3 },
    { label: "🚫 CONTRAINDICATIONS",   value: drug.contraindications,  col: C.accent1 },
    { label: "💊 DOSE",                 value: drug.dose,               col: C.accent2 },
    { label: "⚠️ MAX DOSE",            value: drug.maxDose,            col: C.accent6 },
    { label: "🧪 DILUTION / HOW TO USE",value: drug.dilution,          col: C.accent5 },
    { label: "🗓️ SHELF LIFE",          value: drug.shelfLife,          col: C.accent7 },
    { label: "⏱️ HALF-LIFE",           value: drug.halfLife,           col: C.accent9 },
  ];

  const cols4 = 4, rows2 = 2;
  const cardW = 3.15, cardH = 2.9;
  const gapX = 0.1, gapY = 0.12;
  const startX = 0.1, startY = 0.65;

  cards.forEach((card, i) => {
    const col2 = i % cols4;
    const row2 = Math.floor(i / cols4);
    const x = startX + col2 * (cardW + gapX);
    const y = startY + row2 * (cardH + gapY);

    // Card bg
    slide.addShape(pres.shapes.RECTANGLE, {
      x, y, w: cardW, h: cardH,
      fill: { color: C.panel },
      shadow: { type: "outer", color: "000000", blur: 4, offset: 2, angle: 135, opacity: 0.2 },
    });

    // Label bar
    slide.addShape(pres.shapes.RECTANGLE, {
      x, y, w: cardW, h: 0.32,
      fill: { color: card.col },
    });
    slide.addText(card.label, {
      x: x + 0.07, y, w: cardW - 0.07, h: 0.32,
      fontSize: 9.5, bold: true, color: C.white,
      valign: "middle", fontFace: "Arial", margin: 0,
    });

    // Content
    slide.addText(card.value, {
      x: x + 0.1, y: y + 0.34, w: cardW - 0.2, h: cardH - 0.44,
      fontSize: 9.5, color: C.lightGray,
      valign: "top", fontFace: "Arial",
      wrap: true, autoFit: true,
    });
  });

  // Footer
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: SH - 0.22, w: SW, h: 0.22, fill: { color: C.hdr } });
  slide.addText(`Drug ${idx + 1} of ${drugs.length}  |  ${drug.name}  |  Educational Reference Chart`, {
    x: 0.2, y: SH - 0.22, w: 12.9, h: 0.22,
    fontSize: 8, color: "4A6A8A", align: "center", valign: "middle",
  });
});

// ─── SLIDE 18: SUMMARY TABLE ─────────────────────────────────────────────────
{
  const slide = pres.addSlide();
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: SH, fill: { color: C.bg } });
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: 0.55, fill: { color: C.accent4 } });
  slide.addText("EMERGENCY DRUGS — AT A GLANCE SUMMARY", {
    x: 0.3, y: 0.06, w: 12.7, h: 0.43,
    fontSize: 22, bold: true, color: C.white, fontFace: "Arial", valign: "middle",
  });

  const headers = ["DRUG", "CATEGORY", "DOSE", "HALF-LIFE", "KEY NOTE"];
  const rows = drugs.map(d => [
    d.name,
    d.category.split("|")[0].trim(),
    d.dose.split("\n")[0],
    d.halfLife,
    d.contraindications.split(",")[0],
  ]);

  const colWidths = [2.2, 2.4, 3.8, 1.3, 3.3];
  const rowH = 0.365;
  const startY = 0.65;
  const startX = 0.1;

  // Header row
  headers.forEach((h, ci) => {
    let cx = startX;
    for (let k = 0; k < ci; k++) cx += colWidths[k];
    slide.addShape(pres.shapes.RECTANGLE, {
      x: cx, y: startY, w: colWidths[ci], h: rowH,
      fill: { color: C.accent4 },
    });
    slide.addText(h, {
      x: cx + 0.05, y: startY, w: colWidths[ci] - 0.1, h: rowH,
      fontSize: 9, bold: true, color: C.white, valign: "middle",
    });
  });

  // Data rows
  rows.forEach((row, ri) => {
    const ry = startY + (ri + 1) * rowH;
    const rowColor = ri % 2 === 0 ? C.panel : C.panelAlt;
    const dotColor = drugs[ri].color;
    row.forEach((cell, ci) => {
      let cx = startX;
      for (let k = 0; k < ci; k++) cx += colWidths[k];
      slide.addShape(pres.shapes.RECTANGLE, {
        x: cx, y: ry, w: colWidths[ci], h: rowH,
        fill: { color: rowColor },
        line: { color: C.bg, width: 0.5 },
      });
      if (ci === 0) {
        slide.addShape(pres.shapes.RECTANGLE, {
          x: cx, y: ry, w: 0.05, h: rowH,
          fill: { color: dotColor },
        });
      }
      slide.addText(cell, {
        x: cx + (ci === 0 ? 0.1 : 0.05), y: ry, w: colWidths[ci] - 0.15, h: rowH,
        fontSize: 8, color: C.lightGray, valign: "middle", wrap: true, autoFit: true,
      });
    });
  });

  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: SH - 0.22, w: SW, h: 0.22, fill: { color: C.hdr } });
  slide.addText("Emergency Drug Reference | For educational purposes only | Always verify with current local formulary", {
    x: 0.2, y: SH - 0.22, w: 12.9, h: 0.22,
    fontSize: 8, color: "4A6A8A", align: "center", valign: "middle",
  });
}

// ─── Write file ───────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/emergency-drugs-poster/Emergency_Drug_Chart.pptx" })
  .then(() => console.log("SUCCESS: File written"))
  .catch(e => console.error("ERROR:", e));

const pptxgen = require("pptxgenjs");
const pres = new pptxgen();
pres.layout = "LAYOUT_WIDE"; // 13.3" x 7.5"

// ─── Color Palette ───────────────────────────────────────────────────────────
const C = {
  bg:       "0A1628",
  panel:    "0D1F3C",
  panelAlt: "0E2445",
  accent1:  "E8383D",
  accent2:  "F4A61A",
  accent3:  "27AE60",
  accent4:  "2E86DE",
  accent5:  "9B59B6",
  accent6:  "E67E22",
  accent7:  "1ABC9C",
  accent8:  "E74C3C",
  accent9:  "3498DB",
  accent10: "8E44AD",
  white:    "FFFFFF",
  lightGray:"C8D6E5",
  yellow:   "F9CA24",
  hdr:      "152744",
};

// ─── Drug Data ────────────────────────────────────────────────────────────────
const drugs = [
  {
    name: "LABETALOL",
    color: C.accent1,
    category: "Alpha/Beta-Blocker | Antihypertensive",
    mechanism: "Non-selective beta-blocker + selective alpha-1 blocker. Reduces heart rate, SVR and BP simultaneously. Ratio alpha:beta block = 1:7 (IV).",
    indications: "Hypertensive emergencies, pre-eclampsia/eclampsia, aortic dissection, phaeochromocytoma crisis, hypertension post-stroke",
    contraindications: "Asthma/COPD, 2nd/3rd degree AV block, cardiogenic shock, bradycardia <50/min, decompensated heart failure",
    dose: "IV bolus: 20 mg over 2 min; repeat 40-80 mg every 10 min\nInfusion: 1-2 mg/min titrated\nOral: 100-400 mg BD",
    maxDose: "Bolus total: 300 mg per session | Infusion: 300 mg/session",
    dilution: "200 mg in 200 mL NS/D5W (1 mg/mL); for bolus use undiluted 5 mg/mL ampoule",
    shelfLife: "Undiluted: 2 years | Diluted: 24 h room temp / 48 h refrigerated",
    halfLife: "5 to 8 hours",
  },
  {
    name: "METOCLOPRAMIDE",
    color: C.accent2,
    category: "D2-Antagonist | Prokinetic | Antiemetic",
    mechanism: "Central and peripheral D2-receptor antagonist + 5-HT3 antagonist. Increases gastric motility, raises lower oesophageal sphincter tone, blocks CTZ.",
    indications: "Nausea/vomiting (all causes), gastroparesis, GORD, post-op ileus, migraine (adjunct), pre-procedure gastric emptying",
    contraindications: "GI obstruction or perforation, phaeochromocytoma, Parkinson's disease, seizure disorders, history of tardive dyskinesia",
    dose: "IV/IM: 10 mg over 1-2 min; Oral: 10 mg TDS before meals\nCRI: 25-75 mg/24 h",
    maxDose: "30 mg/day (adult) | 0.5 mg/kg/day (paediatric)",
    dilution: "10 mg in 50 mL NS, give over 15 min IV (reduces extrapyramidal side effects)",
    shelfLife: "Undiluted: 3 years | Diluted: 48 h protected from light",
    halfLife: "5 to 6 hours",
  },
  {
    name: "TRAMADOL",
    color: C.accent3,
    category: "Weak Opioid Agonist | SNRI | Analgesic",
    mechanism: "Weak mu-opioid receptor agonist + inhibits reuptake of serotonin and noradrenaline in descending pain pathways. Dual central analgesic action.",
    indications: "Moderate to severe acute/chronic pain, post-operative pain, neuropathic pain, musculoskeletal pain",
    contraindications: "MAOIs within 14 days, active seizure disorder, raised ICP, severe respiratory depression, serotonin syndrome risk, children <12 years",
    dose: "IV: 50-100 mg over 10-20 min every 4-6 h\nOral: 50-100 mg every 6 h\nMax: 400 mg/day",
    maxDose: "400 mg/day (oral) | 600 mg/day (IV, monitored setting)",
    dilution: "100 mg diluted in 100 mL NS, infuse over 30 min (slow infusion reduces nausea/vomiting)",
    shelfLife: "Undiluted: 3 years | Diluted: 24 h",
    halfLife: "6-7 h (active metabolite O-desmethyltramadol: ~9 h)",
  },
  {
    name: "AVIL (Pheniramine)",
    color: C.accent4,
    category: "H1-Antihistamine | Antiallergic",
    mechanism: "Competitive H1-receptor antagonist. Blocks histamine-mediated vasodilation, bronchoconstriction, pruritus and oedema. Also mild CNS sedation.",
    indications: "Allergic reactions, anaphylaxis (adjunct to adrenaline), urticaria, angioedema, pruritus, transfusion reactions, insect bites/stings",
    contraindications: "Acute asthma (use cautiously), neonates, nursing mothers, concurrent MAOIs, narrow-angle glaucoma, benign prostatic hypertrophy",
    dose: "IM/IV: 22.75 mg (1 mL) to 45.5 mg (2 mL) slow IV\nOral: 25-50 mg twice to three times daily",
    maxDose: "100 mg/24 h (IV) | 200 mg/24 h (oral)",
    dilution: "Dilute in 10 mL NS, give over 2-3 min slow IV. IM can be given undiluted.",
    shelfLife: "3 years | Diluted: 8 h",
    halfLife: "16 to 19 hours",
  },
  {
    name: "TRANEXAMIC ACID",
    color: C.accent5,
    category: "Antifibrinolytic | Haemostatic",
    mechanism: "Inhibits conversion of plasminogen to plasmin by occupying lysine binding sites on plasminogen. Prevents fibrin clot dissolution (antifibrinolysis).",
    indications: "Trauma haemorrhage (within 3 h), postpartum haemorrhage (PPH), surgical bleeding, menorrhagia, epistaxis, haemoptysis, dental extraction in haemophiliacs",
    contraindications: "Active thromboembolic disease (DVT/PE), subarachnoid haemorrhage (controversial), renal failure (reduce dose), history of seizures (high dose IV)",
    dose: "Trauma/PPH: 1 g IV over 10 min STAT; then 1 g over 8 h\nSurgery: 1-1.5 g IV pre-op",
    maxDose: "2 g per episode (trauma); 3-4 g/day (surgical/gynaecological)",
    dilution: "1 g (10 mL) in 100 mL NS or D5W; infuse over 10-20 min. NEVER rapid IV bolus (causes convulsions).",
    shelfLife: "4-5 years | Diluted: 8 h at room temperature",
    halfLife: "2 to 3 hours",
  },
  {
    name: "TAPENTADOL",
    color: C.accent6,
    category: "Strong Opioid | NRI | Dual Mechanism Analgesic",
    mechanism: "Dual mechanism: mu-opioid receptor agonist (like morphine) + noradrenaline reuptake inhibitor (like SNRIs). Multimodal central analgesia with less opioid burden.",
    indications: "Moderate-severe acute pain, chronic musculoskeletal/neuropathic pain, post-operative pain, diabetic peripheral neuropathy",
    contraindications: "MAOIs within 14 days, severe asthma/respiratory depression, paralytic ileus, patients <18 yrs (IR form), uncontrolled epilepsy",
    dose: "Oral IR: 50-100 mg every 4-6 h; 2nd dose 1 h after 1st if needed\nOral ER: 50-250 mg BD",
    maxDose: "Day 1: 700 mg; thereafter 600 mg/day (IR) | ER: 500 mg/day",
    dilution: "Oral formulation only (no IV preparation available). Take with or without food.",
    shelfLife: "3 years",
    halfLife: "4 to 5 hours",
  },
  {
    name: "PHENYTOIN",
    color: C.accent7,
    category: "Antiepileptic | Na-Channel Blocker | Class IB Antiarrhythmic",
    mechanism: "Blocks voltage-gated Na+ channels (use-dependent blockade). Decreases neuronal membrane excitability and suppresses epileptiform firing without CNS depression.",
    indications: "Status epilepticus (2nd line after BZDs), generalised tonic-clonic seizures, partial seizures, post-neurosurgical prophylaxis, digoxin-induced arrhythmia",
    contraindications: "2nd/3rd degree AV block, sinus bradycardia, Adams-Stokes syndrome, concurrent delavirdine use, hypersensitivity to hydantoins",
    dose: "Loading: 15-20 mg/kg IV at max 50 mg/min\nMaintenance: 4-6 mg/kg/day divided BD-TDS\nTherapeutic level: 10-20 mcg/mL",
    maxDose: "Loading dose max 30 mg/kg | Rate NEVER exceed 50 mg/min (risk: cardiac arrhythmia, hypotension)",
    dilution: "Dilute in NS ONLY (precipitates in D5W!); final conc <=6.7 mg/mL. Use 0.22 micron in-line filter. Flush line with NS.",
    shelfLife: "2-5 years | Diluted: use within 1 hour (precipitates rapidly)",
    halfLife: "7-42 h (dose-dependent, saturable/Michaelis-Menten kinetics)",
  },
  {
    name: "LORAZEPAM",
    color: C.accent8,
    category: "Benzodiazepine | Anticonvulsant | Anxiolytic",
    mechanism: "Positive allosteric modulator of GABA-A receptor. Increases frequency of Cl- channel opening, enhancing inhibitory neurotransmission. No active metabolites.",
    indications: "Status epilepticus (1st-line IV), acute severe anxiety/agitation, procedural sedation, alcohol withdrawal seizures, pre-anaesthetic, acute mania",
    contraindications: "Acute angle-closure glaucoma, myasthenia gravis, severe respiratory depression, obstructive sleep apnoea, 1st trimester pregnancy",
    dose: "Seizure: 0.1 mg/kg IV (usual 4 mg adult); may repeat x1 after 5 min\nAnxiety: 0.5-2 mg IV/IM every 6-8 h",
    maxDose: "8 mg total per seizure episode | 10 mg/day (anxiety)",
    dilution: "Dilute 1:1 with NS, D5W or sterile water for IV use. Rate <=2 mg/min. IM can be given undiluted.",
    shelfLife: "2-3 years | Diluted: 24 h refrigerated (expires rapidly at room temp)",
    halfLife: "10 to 20 hours (no active metabolite - advantageous in elderly/hepatic)",
  },
  {
    name: "ONDANSETRON",
    color: C.accent9,
    category: "5-HT3 Receptor Antagonist | Antiemetic",
    mechanism: "Selective 5-HT3 receptor antagonist at peripheral vagal nerve terminals and central chemoreceptor trigger zone (CTZ). Blocks serotonin-mediated emetic reflex.",
    indications: "Post-operative nausea/vomiting (PONV), chemotherapy/radiotherapy-induced N&V, intractable vomiting, gastroenteritis, pre-procedure antiemetic",
    contraindications: "Congenital long QT syndrome, concurrent apomorphine (severe hypotension/loss of consciousness), caution with other QT-prolonging drugs",
    dose: "IV: 4-8 mg over 15 min (PONV); 8 mg over 15 min (chemo-induced)\nOral: 8 mg BD-TDS\nODT: 8 mg sublingual",
    maxDose: "32 mg/day; single IV dose capped at 16 mg (FDA 2012 safety advisory re: QT prolongation)",
    dilution: "4-8 mg in 50 mL NS or D5W, infuse over 15 min. Undiluted 2 mg/mL for slow IV push.",
    shelfLife: "3-5 years | Diluted: 48 h at 2-8 degrees C or 24 h room temperature",
    halfLife: "3 to 6 hours",
  },
  {
    name: "NORADRENALINE",
    color: C.accent10,
    category: "Vasopressor | Alpha-1/Alpha-2/Beta-1 Agonist",
    mechanism: "Potent alpha-1 and alpha-2 agonist (vasoconstriction, increases SVR) + mild beta-1 agonism (mild inotropy). Increases MAP without major tachycardia.",
    indications: "Septic shock (1st-line vasopressor per Surviving Sepsis Guidelines), neurogenic shock, refractory hypotension, distributive shock states",
    contraindications: "Hypovolaemia (correct first before starting), mesenteric/peripheral vascular thrombosis, cyclopropane or halothane anaesthesia",
    dose: "Start: 0.01-0.05 mcg/kg/min; titrate to MAP >=65 mmHg\nUsual range: 0.1-2 mcg/kg/min",
    maxDose: "Up to 3-5 mcg/kg/min; no absolute maximum - titrate to haemodynamic targets. High dose causes excessive vasoconstriction.",
    dilution: "4-8 mg in 250 mL D5W or NS (16-32 mcg/mL). Preferably via central line. Peripheral extravasation causes tissue necrosis.",
    shelfLife: "18 months | Diluted: 24 h protected from light (oxidises rapidly)",
    halfLife: "Approx 2-3 minutes (ultra-short; requires continuous infusion)",
  },
  {
    name: "ADRENALINE (Epinephrine)",
    color: C.accent1,
    category: "Alpha/Beta Agonist | Vasopressor | First-Line Anaphylaxis",
    mechanism: "Alpha-1: vasoconstriction (increases MAP, reduces mucosal oedema); Beta-1: increases HR and contractility; Beta-2: bronchodilation, inhibits mast cell mediator release.",
    indications: "Anaphylaxis (1st-line IM), cardiac arrest (VF/pVT/PEA/asystole), cardiogenic shock, severe bronchospasm, croup (nebulised), septic shock adjunct",
    contraindications: "No absolute contraindications in life-threatening emergencies. Relative: arrhythmias, severe coronary artery disease, thyrotoxicosis.",
    dose: "Anaphylaxis: 0.5 mg IM (0.5 mL of 1:1000) into anterolateral thigh\nCardiac arrest: 1 mg IV every 3-5 min (1:10,000)\nInfusion: 0.01-1 mcg/kg/min",
    maxDose: "Cardiac arrest: no fixed maximum; Anaphylaxis: repeat 0.5 mg IM every 5 min as needed",
    dilution: "Infusion: 1 mg in 100 mL NS (10 mcg/mL). Cardiac arrest: 10 mL of 1:10,000 solution (0.1 mg/mL). IM anaphylaxis: undiluted 1:1000.",
    shelfLife: "18-24 months | Diluted: 24 h (protect from light). Discard if discoloured/brown.",
    halfLife: "Approx 2-3 minutes (continuous infusion required for sustained effect)",
  },
  {
    name: "DOBUTAMINE",
    color: C.accent3,
    category: "Beta-1/Beta-2 Agonist | Inotrope | Cardiogenic Support",
    mechanism: "Selective beta-1 agonist + mild beta-2 agonism. Increases myocardial contractility and cardiac output. Modest chronotropy. Reduces SVR (afterload reduction).",
    indications: "Cardiogenic shock, acute decompensated heart failure with reduced CO, post-cardiac surgery low output syndrome, pharmacological stress echocardiography",
    contraindications: "Hypertrophic obstructive cardiomyopathy (HOCM), uncorrected hypovolaemia, AF/flutter (may increase ventricular rate), severe aortic stenosis",
    dose: "Start 2.5 mcg/kg/min; usual range 2.5-20 mcg/kg/min\nTitrate to cardiac output, BP and clinical response",
    maxDose: "40 mcg/kg/min (rarely needed; most effect achieved by 20 mcg/kg/min)",
    dilution: "250 mg in 250 mL D5W or NS (1 mg/mL). Do NOT mix with sodium bicarbonate (inactivation). Use infusion pump.",
    shelfLife: "2 years | Diluted: 24 h at room temperature (mild pinkish discolouration - stable if slight)",
    halfLife: "Approx 2 minutes (requires continuous infusion)",
  },
  {
    name: "DOPAMINE",
    color: C.accent2,
    category: "Catecholamine | Dose-Dependent Vasopressor/Inotrope",
    mechanism: "Dose-dependent: Low (1-5 mcg/kg/min): D1/D2 dopaminergic - renal/mesenteric vasodilation; Mid (5-10): beta-1 - increases CO; High (>10): alpha-1 - vasoconstriction.",
    indications: "Cardiogenic shock, septic shock (2nd-line to noradrenaline), haemodynamic support post-cardiac surgery, symptomatic bradycardia (adjunct)",
    contraindications: "Phaeochromocytoma, uncorrected tachyarrhythmias or VF, hypovolaemia (correct first), MAOIs within 14 days, sulphite sensitivity",
    dose: "Renal dose: 1-5 mcg/kg/min | Inotropic: 5-10 mcg/kg/min | Vasopressor: 10-20 mcg/kg/min",
    maxDose: "50 mcg/kg/min (extreme cases); titrate to haemodynamic response",
    dilution: "400-800 mg in 250 mL D5W or NS. Use infusion pump only. Extravasation: phentolamine 5-10 mg local injection.",
    shelfLife: "2-3 years | Diluted: 24 h at room temperature",
    halfLife: "Approx 2 minutes (requires continuous infusion)",
  },
  {
    name: "ATROPINE",
    color: C.accent4,
    category: "Anticholinergic | Parasympatholytic | Antidote",
    mechanism: "Competitive muscarinic receptor antagonist. Blocks vagal tone: increases HR, decreases secretions (salivary/bronchial), bronchodilation, mydriasis, decreases GI motility.",
    indications: "Symptomatic bradycardia (sinus, 1st/2nd degree AV block), organophosphate/nerve agent poisoning, pre-op antisecretory, bradycardia during anaesthesia",
    contraindications: "Angle-closure glaucoma, myasthenia gravis, existing tachycardia, urinary retention/BPH, GI obstruction, pyloric stenosis",
    dose: "Bradycardia: 0.5-1 mg IV every 3-5 min (max 3 mg)\nOrganophosphate: 2-4 mg IV every 5-10 min (titrate to dry secretions)\nPaeds: 0.02 mg/kg IV",
    maxDose: "Bradycardia: 3 mg total | OP poisoning: no upper limit (clinical titration to secretion drying)",
    dilution: "Available as 0.6 mg/mL or 1 mg/mL. May dilute in 10 mL NS. For bradycardia: give as rapid IV push.",
    shelfLife: "3-5 years | Diluted: 24 h",
    halfLife: "2 to 3 hours",
  },
  {
    name: "NITROGLYCERIN (GTN)",
    color: C.accent5,
    category: "Organic Nitrate | Vasodilator | Antianginal",
    mechanism: "Converted to nitric oxide (NO) -> activates guanylyl cyclase -> increases cGMP -> smooth muscle relaxation. Low dose: venodilation (decreases preload). High dose: arteriodilation (decreases afterload).",
    indications: "Acute angina/ACS (SL), STEMI adjunct, hypertensive emergency with ACS, acute decompensated HF (high filling pressures), oesophageal spasm",
    contraindications: "Systolic BP <90 mmHg, right ventricular infarction, PDE-5 inhibitors (sildenafil/tadalafil within 24-48 h), severe aortic stenosis, raised ICP",
    dose: "SL: 0.3-0.4 mg every 5 min x 3 doses\nIV infusion: Start 5-10 mcg/min; titrate up to 200 mcg/min",
    maxDose: "SL: 3 doses; IV: up to 400 mcg/min (haemodynamic-guided); tolerance develops after 24 h",
    dilution: "50 mg in 250 mL D5W (200 mcg/mL). Use glass bottles and non-PVC tubing (adsorbs to PVC). Protect from light.",
    shelfLife: "2-3 years | Diluted: 24 h (glass, non-PVC only). SL tablets: 6-12 months after opening.",
    halfLife: "1-3 minutes (IV); patch ~20 min; tolerance with continuous infusion >24 h",
  },
  {
    name: "IV FLUIDS",
    color: C.accent7,
    category: "Crystalloids/Colloids | Volume Resuscitation | Electrolyte Replacement",
    mechanism: "NS 0.9%: isotonic crystalloid, expands ECF (only 25% stays intravascular after 1 h). Hartmann's/LR: balanced electrolyte, less hyperchloraemic acidosis. Colloids: oncotic pressure expansion.",
    indications: "Hypovolaemia, shock resuscitation, surgical maintenance fluids, electrolyte replacement, drug dilution vehicle, DKA protocol, burns resuscitation, sepsis",
    contraindications: "Pulmonary oedema (excess administration), NS in hyperchloraemic acidosis or renal failure, D5W in cerebral oedema or hyponatraemia",
    dose: "Resuscitation: 500 mL crystalloid bolus over 15 min; reassess and repeat\nMaintenance: 25-30 mL/kg/day\nDKA: 1 L NS in first hour",
    maxDose: "Goal-directed therapy. Avoid fluid overload. Limit NS to prevent hyperchloraemic acidosis. TISS/SOFA monitoring.",
    dilution: "Ready to use. Warm to 37 degrees C for large volume resuscitation. Always check drug compatibility before adding.",
    shelfLife: "2-5 years (sealed) | Once opened: single-use session only",
    halfLife: "NS intravascular t1/2: ~1 h; Albumin 5%: ~16 h; Hartmann's: ~30 min",
  },
];

const SW = 13.3, SH = 7.5;

// ─── SLIDE 1: COVER ──────────────────────────────────────────────────────────
{
  const slide = pres.addSlide();
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: SH, fill: { color: C.bg } });

  // Decorative bars
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: 0.1, fill: { color: C.accent1 } });
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0.1, w: SW, h: 0.05, fill: { color: C.accent2 } });
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: SH - 0.1, w: SW, h: 0.1, fill: { color: C.accent3 } });

  // Side accent
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: 0.12, h: SH, fill: { color: C.accent4 } });

  // Main title
  slide.addText("EMERGENCY DRUG", {
    x: 0.3, y: 1.0, w: 12.7, h: 1.4,
    fontSize: 72, bold: true, color: C.white,
    align: "center", fontFace: "Arial",
  });
  slide.addText("QUICK REFERENCE CHART", {
    x: 0.3, y: 2.5, w: 12.7, h: 0.9,
    fontSize: 38, bold: true, color: C.accent2,
    align: "center", fontFace: "Arial",
  });

  // Divider
  slide.addShape(pres.shapes.RECTANGLE, { x: 2.5, y: 3.55, w: 8.3, h: 0.05, fill: { color: C.accent4 } });

  slide.addText("Mechanism  |  Indications  |  Contraindications  |  Dose  |  Max Dose  |  Dilution  |  Shelf Life  |  Half-Life", {
    x: 0.3, y: 3.7, w: 12.7, h: 0.55,
    fontSize: 15, color: C.lightGray,
    align: "center", fontFace: "Arial", italic: true,
  });

  // Drug names
  const drugList1 = drugs.slice(0,8).map(d => d.name).join("   |   ");
  const drugList2 = drugs.slice(8).map(d => d.name).join("   |   ");
  slide.addText(drugList1, {
    x: 0.3, y: 4.4, w: 12.7, h: 0.4,
    fontSize: 10, color: C.accent7, align: "center", fontFace: "Arial",
  });
  slide.addText(drugList2, {
    x: 0.3, y: 4.82, w: 12.7, h: 0.4,
    fontSize: 10, color: C.accent7, align: "center", fontFace: "Arial",
  });

  // Badges
  const badges = ["16 Emergency Drugs", "Complete Reference", "ICU / Emergency Use"];
  const bColors = [C.accent1, C.accent4, C.accent3];
  badges.forEach((b, i) => {
    const bx = 1.8 + i * 3.3;
    slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
      x: bx, y: 5.45, w: 2.8, h: 0.55,
      fill: { color: bColors[i] }, rectRadius: 0.08,
    });
    slide.addText(b, {
      x: bx, y: 5.45, w: 2.8, h: 0.55,
      fontSize: 13, color: C.white, bold: true,
      align: "center", valign: "middle",
    });
  });

  slide.addText("For educational and clinical reference purposes | Always verify with current local formulary and guidelines", {
    x: 0.3, y: 7.05, w: 12.7, h: 0.3,
    fontSize: 9, color: "4A6A8A", align: "center", italic: true,
  });
}

// ─── SLIDES 2-17: One drug per slide ─────────────────────────────────────────
drugs.forEach((drug, idx) => {
  const slide = pres.addSlide();

  // Background
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: SH, fill: { color: C.bg } });

  // Top header bar
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: 0.58, fill: { color: drug.color } });

  // Number badge
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 0.15, y: 0.09, w: 0.4, h: 0.38,
    fill: { color: "00000040" }, rectRadius: 0.05,
  });
  slide.addText(String(idx + 1), {
    x: 0.15, y: 0.09, w: 0.4, h: 0.38,
    fontSize: 14, bold: true, color: C.white,
    align: "center", valign: "middle",
  });

  // Drug name
  slide.addText(drug.name, {
    x: 0.65, y: 0.06, w: 9.5, h: 0.48,
    fontSize: 28, bold: true, color: C.white,
    fontFace: "Arial", valign: "middle", margin: 0,
  });

  // Category tag
  slide.addShape(pres.shapes.ROUNDED_RECTANGLE, {
    x: 10.3, y: 0.1, w: 2.85, h: 0.38,
    fill: { color: "00000050" }, rectRadius: 0.06,
  });
  slide.addText(drug.category, {
    x: 10.3, y: 0.1, w: 2.85, h: 0.38,
    fontSize: 8.5, color: C.white, bold: true,
    align: "center", valign: "middle", wrap: true,
  });

  // 8 cards in 4x2 grid
  const cardData = [
    { label: "MECHANISM OF ACTION",         value: drug.mechanism,          accent: C.accent4 },
    { label: "INDICATIONS",                  value: drug.indications,        accent: C.accent3 },
    { label: "CONTRAINDICATIONS",            value: drug.contraindications,  accent: C.accent1 },
    { label: "DOSE",                         value: drug.dose,               accent: C.accent2 },
    { label: "MAXIMUM DOSE",                 value: drug.maxDose,            accent: C.accent6 },
    { label: "DILUTION / HOW TO USE",        value: drug.dilution,           accent: C.accent5 },
    { label: "SHELF LIFE",                   value: drug.shelfLife,          accent: C.accent7 },
    { label: "HALF-LIFE",                    value: drug.halfLife,           accent: C.accent9 },
  ];

  const cardW = 3.17;
  const cardH = 2.88;
  const gapX = 0.09;
  const gapY = 0.1;
  const startX = 0.08;
  const startY = 0.67;

  cardData.forEach((card, i) => {
    const col = i % 4;
    const row = Math.floor(i / 4);
    const x = startX + col * (cardW + gapX);
    const y = startY + row * (cardH + gapY);

    // Card background
    slide.addShape(pres.shapes.RECTANGLE, {
      x, y, w: cardW, h: cardH,
      fill: { color: C.panel },
      shadow: { type: "outer", color: "000000", blur: 5, offset: 2, angle: 135, opacity: 0.25 },
    });

    // Left accent stripe
    slide.addShape(pres.shapes.RECTANGLE, {
      x, y, w: 0.06, h: cardH,
      fill: { color: card.accent },
    });

    // Label bar
    slide.addShape(pres.shapes.RECTANGLE, {
      x: x + 0.06, y, w: cardW - 0.06, h: 0.3,
      fill: { color: card.accent },
    });
    slide.addText(card.label, {
      x: x + 0.12, y, w: cardW - 0.18, h: 0.3,
      fontSize: 9, bold: true, color: C.white,
      valign: "middle", fontFace: "Arial", margin: 0,
    });

    // Value text
    slide.addText(card.value, {
      x: x + 0.1, y: y + 0.32, w: cardW - 0.2, h: cardH - 0.42,
      fontSize: 9.5, color: C.lightGray,
      valign: "top", fontFace: "Arial",
      wrap: true, autoFit: true,
    });
  });

  // Footer
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: SH - 0.2, w: SW, h: 0.2, fill: { color: C.hdr } });
  slide.addText(`Drug ${idx + 1} of ${drugs.length}  |  ${drug.name}  |  Emergency Drug Reference Chart`, {
    x: 0.2, y: SH - 0.2, w: 12.9, h: 0.2,
    fontSize: 7.5, color: "4A6A8A", align: "center", valign: "middle",
  });
});

// ─── SLIDE 18: SUMMARY TABLE ─────────────────────────────────────────────────
{
  const slide = pres.addSlide();
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: SH, fill: { color: C.bg } });
  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: 0, w: SW, h: 0.58, fill: { color: C.accent4 } });
  slide.addText("EMERGENCY DRUGS  |  AT-A-GLANCE SUMMARY", {
    x: 0.3, y: 0.06, w: 12.7, h: 0.46,
    fontSize: 24, bold: true, color: C.white, fontFace: "Arial", valign: "middle",
  });

  const headers = ["DRUG", "CATEGORY", "STANDARD DOSE", "HALF-LIFE", "KEY CONTRAINDICATION"];
  const colWidths = [2.2, 2.5, 3.6, 1.3, 3.4];
  const rowH = 0.355;
  const startY = 0.66;
  const startX = 0.08;

  // Header
  headers.forEach((h, ci) => {
    let cx = startX;
    for (let k = 0; k < ci; k++) cx += colWidths[k];
    slide.addShape(pres.shapes.RECTANGLE, {
      x: cx, y: startY, w: colWidths[ci], h: rowH,
      fill: { color: C.accent4 },
      line: { color: C.bg, width: 0.5 },
    });
    slide.addText(h, {
      x: cx + 0.06, y: startY, w: colWidths[ci] - 0.12, h: rowH,
      fontSize: 9, bold: true, color: C.white, valign: "middle",
    });
  });

  drugs.forEach((drug, ri) => {
    const ry = startY + (ri + 1) * rowH;
    const rowColor = ri % 2 === 0 ? C.panel : C.panelAlt;
    const row = [
      drug.name,
      drug.category.split("|")[0].trim(),
      drug.dose.split("\n")[0],
      drug.halfLife,
      drug.contraindications.split(",")[0],
    ];
    row.forEach((cell, ci) => {
      let cx = startX;
      for (let k = 0; k < ci; k++) cx += colWidths[k];
      slide.addShape(pres.shapes.RECTANGLE, {
        x: cx, y: ry, w: colWidths[ci], h: rowH,
        fill: { color: rowColor },
        line: { color: C.bg, width: 0.5 },
      });
      // Color dot on drug name column
      if (ci === 0) {
        slide.addShape(pres.shapes.RECTANGLE, {
          x: cx, y: ry, w: 0.06, h: rowH,
          fill: { color: drug.color },
        });
      }
      slide.addText(cell, {
        x: cx + (ci === 0 ? 0.1 : 0.06), y: ry,
        w: colWidths[ci] - (ci === 0 ? 0.16 : 0.12), h: rowH,
        fontSize: 7.8, color: C.lightGray, valign: "middle", wrap: true, autoFit: true,
      });
    });
  });

  slide.addShape(pres.shapes.RECTANGLE, { x: 0, y: SH - 0.2, w: SW, h: 0.2, fill: { color: C.hdr } });
  slide.addText("Emergency Drug Reference | For educational purposes only | Always verify with current local formulary and clinical guidelines", {
    x: 0.2, y: SH - 0.2, w: 12.9, h: 0.2,
    fontSize: 7.5, color: "4A6A8A", align: "center", valign: "middle",
  });
}

// ─── Write ─────────────────────────────────────────────────────────────────────
pres.writeFile({ fileName: "/home/daytona/workspace/emergency-drugs-poster/Emergency_Drug_Chart.pptx" })
  .then(() => console.log("SUCCESS: File written"))
  .catch(e => console.error("ERROR:", e));